1. No category

Title
Concomitant Use of Antiplatelet
Therapy with Edoxaban or Warfarin in
Patients with Atrial Fibrillation in the
ENGAGE AF–TIMI 48 Trial
Presenter (Oral) Haiyan Xu, MD, PhD
Session Treatment of Arrhythmias: Pharmacologic: Novel
Anticoagulants
Time 3:45 – 3:55 PM
Location S401bcd
Title
Efficacy and Safety of Edoxaban for the
Management of Elderly Patients with
Atrial Fibrillation: ENGAGE AF–TIMI 48
Presenter (Oral) Eri Toda Kato, MD, PhD
Session Treatment of Arrhythmias: Pharmacologic:
Novel Anticoagulants
Time 4:00 – 4:10 PM
Location S401bcd
wednesday, November 19th
Title
Heart Failure Signals with Diabetes
Drugs: PPAR-Gamma, PPAR-Alpha/
Gamma, and DPP 4 Inhibitors
Presenter (Oral) Benjamin M. Scirica, MD, MPH
Session Failure Is Not an Option: The Intersection of
Diabetes and Heart Failure Epidemics
Time 9:45 – 10:00 AM
About the TIMI Study Group
Since its inception in 1984, the principal goal of the
TIMI Study Group has been to conduct high quality
clinical trials that enhance the care of patients suffering
from cardiovascular disease and its risk factors. TIMI
has led a wide array of phase 1 to phase 4 trials, as
well as registries. These have ranged in size from less
than 30 to more than 25,000 subjects. The interventions
studied include fibrinolytic, antithrombotic, anti-platelet,
anti-ischemic, lipid lowering, anti-inflammatory, and
anti-diabetic agents as well as percutaneous coronary
intervention. In addition, the TIMI Study Group has used
its growing database of more than 300,000 subjects
and their clinical findings, electrocardiograms, angiograms, biomarkers, and genotypes to enhance the
understanding of cardiovascular disease and its risk
factors. An important corollary goal has been to train
the next generation of clinical investigators. TIMI is
especially proud of these trainees who have assumed
leadership positions in leading institutions around
the world.
Location S100ab
Title
Efficacy and Safety of Edoxaban Compared
with Warfarin in Patients With Atrial
Fibrillation and Heart Failure: Insights
From ENGAGE AF–TIMI 48
Presenter (Poster) Giulia Magnani, MD
Session Heart Failure: Outcomes and Clinical Trials
Time 9:30 – 11:00 AM
Location South Hall A2, Core 5, Poster 12680
Information is current as of November 17, 2014.
TIMI Study Group
350 Longwood Avenue
Office Level One
Boston, Massachusetts 02115
617.278.0145 or
1.800.385.4444
[email protected]
www.timi.org
twitter: @TIMIstudygroup
en strat . Re dict
n vati n ac in
g
o
i
o
t
n
r
re
e
c
n
e
is
far conse inog olys asmi vativ arctio s to p rome
b
r
pl
sm
nf
el
nd
d
an e pla throm ssue conse dial i I lev ry sy ts in
a
ti
u
e
d
in
en
ar
tiss of th ts of e an yoc opon coron ic ev ults o
m tr
m
ec
e
ts
siv
es
sul l. Ef f inva wave cific acut ische on. R The
e
i
h
y
l.
c
ia
II tr f earl on-Q iac-sp s wit ardia farct B tria meth
c
o
A
d n rd ent
l in 11
son na an al. Ca pati h and ardia IMI) MI: TIMI
c
(T
ri
on g.
in
at
gi
an IIIB T ality ts de e myo ction evati akin ient
I
m
n
v
el
en
rt
ar
TIM f mo preve Q-wa al inf n-ST ision conv tion.
o
A
ta
ec
n
ndi
no
risk apari a/no ocar gina/ tic d tion: resen nts w
y
x
in
p
n
eu
rc
tie
Eno e ang is in m ble a erap l infa nt at in pa s of t
e
n
th
s
ta
ia
e
bl
sta boly r uns and ocard sessm eptid vatio strat
s
p
y
e
om fo
on
ele
thr core ticati ion m risk a retic inor vasiv n my
s os
2014
r
m
in
io
riu
at
risk rogn -elev ore fo e nat ty of arly levat mpar
e
Investigator
e
T
p
o
p
ili
sc
for for S ical f B-ty s. Ab m an n-ST rial. C ts w
re , clin e o me t Presentation
fro d no ed t atien te
o
c
o
u
s ide
fi
n
l
r
z
o
a a domi s in p copr i
s ic va synd bene inSchedule
d
be nost ary dict ang ran egie gly trat
s
n
g
a
he
at
le
re
pro coro to p stab from e str ith t o risk imult
w 16 –t 19 s
T
te
s
november
un
tiv
acu I and ith esult erva ated roach mes: B-typ
p
d
ro
s
ns
sw :r
tre
nin tient ction d co mes er ap synd in, an vs u
rk r y
in
an ro
ar
te
pa
in al inf sive synd ltima rona pro xapar t elev
u
o
y
n
va
di
co
ive
car rly in ronar an. M cute eact of en egme aspir
a
-r
y
d
-s
fib
ea
co
of able r tiro ation in I, C f ficac n-ST an an ed c
v
n
e
b
ay
no
st
to
un hibi ST ele tropo and with tirofi a del coron
in nf
e
ty
s
e
s
IIIa in no ent o . Safe tient receiv sive v acut s mo
e
n
su
th
pa o
n
sm
tio sses eptid in in s wh y inte ts wi e ver ndro
s a tic p epar ome Earl tien ensiv ry sy he
u
o ure
h ndr ial. n pa Int ona tin t
i
d
r
i
r
y
e
tr
t
l.
na ionat ary s lled tegy tria te co er sta nolyt
Z
n
ft
ri
ro
ra
cu
ct
fra coro cont tin st e A to ter a es a d fib ith ST
d
te
h
af
w
om an
ta
acu omize vas Z of t atins outc pirin tion idog
s
d
rc
d
op
sim e
st
ran tive phas ith ls an l to a l infa of cl ercu
p
re
ia
ct
va
s:
g w ve
ser rome erin ein le pidog ocard . Ef fe efore terv
b
n
y
in
d
lo
ow ot
syn pid l ve pr of c for m vatio ment nary ts w
ele at oro ien
ion py
e li cti
Sunday, November 16th
Title
Growth Differentiation Factor-15
Independently Predicts 2 Year Mortality
in Patients with Acute Coronary
Syndrome: Observations from the
A to Z Trial
Presenter (Poster) Ethan C. Kosova, MD
Session Risk Modifiers in Cardiovascular Disease
Time 9:30 – 11:00 AM
Location South Hall A2, Core 7, Poster 16378
Title
Prevalence, Characteristics, Treatment
and In-hospital Outcomes of Diabetes
Mellitus in Patients with Acute
Myocardial Infarction in China from
the China Acute Myocardial Infarction
Registry
Presenter (Poster) Haiyan Xu, MD, PhD
Session Risk Factors for Cardiovascular Events
Time 9:30 – 11:00 AM
Title
Presenter (Poster) Elizabeth A. Magnuson, ScD
Session Anticoagulants for Atrial Fibrillation and Venous
Thromboembolic Disease
Time 3:00 – 4:30 PM
Location South Hall A2, Core 7, Poster #17332
tuesday, November 18th
Title
Presidential Address: Saving and
Improving Lives in the Information Age
Presenter Elliot Antman, MD
Session Opening Session
Time 1:00 – 3:00 PM
Location North Hall B
Session Challenges and Opportunities in
Personalized Medicine
IMPROVE-IT Trial: A comparison
of Ezetimibe/Simvastatin versus
Simvastatin Monotherapy on
Cardiovascular Outcomes after Acute
Coronary Syndromes
Presenter Christopher P. Cannon, MD
Session Late Breaking Trials: Anti-Lipid Therapy and
Prevention of CAD
Time 10:45 AM – 12:13 PM
Location North Hall B
Title
Plasma Omega–3 Fatty Acids and the
Risk of Cardiovascular Death in Patients
after an Acute Coronary Syndrome
Presenter (Poster) Michelle L. O'Donoghue, MD, MPH
Session Insights into the Treatment and Outcomes of
Patients with Acute Coronary Syndromes
Time 3:00 – 4:30 PM
Location South Hall A2, Core 7, Poster 17332
Title
Location S104
Title
Secondary Observations from
SAVOR–TIMI 53 Trial of Saxagliptin
Presenter (Oral) Benjamin M. Scirica, MD, MPH
Session Updates of Cardiovascular Outcomes Trials of Drugs
for Diabetes
Session Lipids, Lipoprotein Metabolism and Biomarkers
Time 3:00 – 4:30 PM
Location South Hall A2, Core 2, Poster 16196
Title
Session Lipids, Lipoprotein Metabolism and Biomarkers
Time 3:00 – 4:30 PM
Location South Hall A2, Core 2, Poster 16865
Title
Presenter (Poster) David A. Morrow
Session Diabetes Mellitus and CVD: Prevention and
Management IV
Time 9:30 – 11:00 AM
Location South Hall A2, Core 2, Poster 17295
Title
IMPROVE-IT Trial: A Comparison of
Ezetimibe/Simvastatin vs. Simvastatin
Monotherapy on Cardiovascular
Outcomes after Acute Coronary
Syndromes
Presenter Christopher P. Cannon, MD
Session Meet The Trialists
Time 1:00 – 1:45 PM
Location Science & Technology Hall, Booth 870
Multimarker Risk Stratification in
Patients with Acute Myocardial
Infarction
Presenter (Poster) Michelle L. O'Donoghue, MD, MPH
Session New Developments in Acute Coronary Syndromes
Time 3:00 – 4:30 PM
Location South Hall A2 – Core 7, Poster 17350
Title
Location S501
Cardiovascular Biomarkers and LongTerm Outcomes in Patients with Type 2
Diabetes Mellitus Treated with Alogiptin
vs. Placebo in the EXAMINE Trial
Safety and Tolerability of Very Low
LDL-C Levels in Patients Treated with 52
Weeks of Evolocumab (AMG 145)
Presenter (Poster) Michael J. Koren, MD
Time 7:45 – 8:00 AM
Title
Impact of Baseline PCSK9 Levels on
the Efficacy of Evolocumab, a
Monoclonal Antibody Against PCSK9
Presenter (Poster) Nihar Desai, MD, MPH
Time 7:30 – 7:45 AM
monday, November 17th
Title
Pharmacogenetics Versus Other
Biomarkers to Guide Clopidogrel Therapy
Presenter (Oral) Jessica L. Mega, MD, MPH
Location South Hall A2, Core 7, Poster 19423
Title
Cost-Effectiveness of Edoxaban vs.
Warfarin in Patients with Atrial
Fibrillation: Results from the ENGAGE AF–
TIMI 48 Economic Study
Systemic, Non-cerebral, Arterial
Embolism in 21,105 Patients with Atrial
Fibrillation Randomized to Edoxaban
or Warfarin: Results from the ENGAGE
AF–TIMI 48 Trial
Presenter (Poster) Bram J. Geller, MD
Session Treatment of Arrhythmias: Pharmacologic – Stroke
and Bleeding in AF
Time 3:00–4:30 PM
Location South Hall A2, Core 4, Poster 18597
Title
Outcomes in Stable Patients with Prior
Atherothrombosis Receiving Vorapaxar
who Present with a New Acute Coronary
Syndrome: Insights from the TRA 2°P–
TIMI 50 Trial
Presenter (Oral) Marc P. Bonaca, MD, MPH
Session Medical Therapy in Chronic Ischemic Heart Disease
Time 3:45 – 3:55 PM
Location S103bc